Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498220 | PMC |
| http://dx.doi.org/10.1016/S2665-9913(20)30333-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics, risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia: a retrospective real-world study of inpatients.
BMC Pharmacol Toxicol
January 2025
Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, 28 Fu Xing Road, Beijing, 100853, China.
Objective: The occurrence of hypofibrinogenemia after tocilizumab treatment has attracted increasing attention, which may cause bleeding and even life-threatening. This study aims to explore the risk factors for tocilizumab-induced hypofibrinogenemia (T-HFIB) and construct a risk prediction model.
Methods: A total of 221 inpatients that received tocilizumab from 2015 to 2023 were retrospectively collected and divided into T-HFIB group or control group.
Tocilizumab in COVID-19: A Double-Edged Sword?
Biomedicines
December 2024
Department of Anesthesia, Critical Care and Rescue Medicine, Collegium Medicum, University in Zielona Góra, 65-046 Zielona Góra, Poland.
SARS-CoV-2 was responsible for the global pandemic. Approximately 10-15% of patients with COVID-19 developed respiratory failure with adult acute respiratory distress syndrome (ARDS), which required treatment in the Intensive Care Unit (ICU). The cytokine storm observed in severe COVID-19 was frequently handled with steroids.
View Article and Find Full Text PDFIL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram.
Biomedicines
December 2024
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
IL-6R inhibitors are widely used in many inflammation-related diseases, especially so during the COVID-19 pandemic. However, their relationship with gastrointestinal perforations (GIPs) has been reported more and more. We comprehensively analyzed IL-6R inhibitors in association with GIPs from the United States FDA Adverse Event Reporting System (FAERS).
View Article and Find Full Text PDFRisk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis.
BMC Infect Dis
January 2025
Intensive Care Unit, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Background: Risk factors for bloodstream infection in patients with COVID-19 in the intensive care unit (ICU) remain unclear. The purpose of this systematic review was to study the risk factors for BSI in patients admitted to ICUs for COVID-19.
Methods: A systematic search was performed on PubMed, EMBASE, Cochrane Library, and Web of Science up to July 2024.
Predictors of Functional Impairment in Severe COVID-19 Patients Two Months After Discharge.
Ther Adv Pulm Crit Care Med
December 2024
Department of Pulmonary and Critical Care Medicine, Hôtel-Dieu de France University, Medical Center (HDFUMC) of the Saint-Joseph University of Beirut (USJ), Beirut, Lebanon.
Background: The Post-COVID-19 Functional Status (PCFS) scale is a validated tool used to measure the functional status of patients discharged from the hospital.
Objectives: To describe the functional limitations of hospitalized COVID-19 patients at the time of discharge and two months afterward, and to identify risk factors associated with functional impairment.
Design: Retrospective study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!